These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 19877119)

  • 1. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
    Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
    J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
    J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Saif MW; Hashmi S; Bell D; Diasio RB
    Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
    Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
    Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
    Koizumi W; Okayasu I; Hyodo I; Sakamoto J; Kojima H;
    Anticancer Drugs; 2008 Sep; 19(8):819-24. PubMed ID: 18690094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
    Hasegawa K; Okamoto H; Kawamura K; Kato R; Kobayashi Y; Sekiya T; Udagawa Y
    Eur J Obstet Gynecol Reprod Biol; 2012 Jul; 163(1):67-70. PubMed ID: 22480411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
    Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
    Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
    Kocakova I; Svoboda M; Kubosova K; Chrenko V; Roubalova E; Krejci E; Sefr R; Slampa P; Frgala T; Zaloudik J
    Neoplasma; 2007; 54(5):447-53. PubMed ID: 17688376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
    Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
    Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
    Saito K; Khan K; Yu SZ; Ronson S; Rhee J; Li G; Van Echo D; Suntharalingam M; O'Malley BW; Li D
    Laryngoscope; 2009 Jan; 119(1):82-8. PubMed ID: 19117293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
    Nishina T; Hyodo I; Miyaike J; Inaba T; Suzuki S; Shiratori Y
    Eur J Cancer; 2004 Jul; 40(10):1566-71. PubMed ID: 15196541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
    Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
    Lay GC; Caraul B; Dessì M; Orrù S; Murtas R; Deidda MA; Farigu R; Farci D; Maxia L; Casula G; Amichetti M
    J Exp Clin Cancer Res; 2007 Mar; 26(1):61-70. PubMed ID: 17550133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
    Ogata Y; Matono K; Sasatomi T; Ishibashi N; Torigoe S; Fukumitsu T; Mizobe T; Yamashita N; Yanagawa T; Shirouzu K
    J Surg Oncol; 2006 Jan; 93(1):47-55. PubMed ID: 16353181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.
    Patel A; Pluim T; Helms A; Bauer A; Tuttle RM; Francis GL
    Cancer Chemother Pharmacol; 2004 May; 53(5):409-14. PubMed ID: 15132128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.